T-Cell Cancer Research Results

T-Cell, T lymphocytes: Click to Expand ⟱
Source:
Type: white blood cell
T cells are white blood cells that play a central role in the adaptive immune response.
Subsets and Function:
Cytotoxic T Cells (CD8+): Recognize and kill infected or malignant cells.
Helper T Cells (CD4+): Assist in orchestrating the immune response by secreting cytokines and supporting the functions of other immune cells.
T cells, particularly CD8+ cytotoxic T cells, can recognize tumor antigens presented on major histocompatibility complex (MHC) molecules and directly kill malignant cells.
Regulatory T Cells (Tregs): Maintain immune tolerance and prevent autoimmunity but may also suppress anti-tumor responses in the tumor microenvironment.
Tumor-Infiltrating Lymphocytes (TILs):
Tumor Microenvironment:
The presence of T cells within tumors, often referred to as tumor-infiltrating lymphocytes, is a key indicator of an ongoing anti-tumor immune response.
Regulatory T Cells (Tregs):
Tregs within the tumor environment may inhibit the activity of cytotoxic T cells through the secretion of immunosuppressive cytokines (e.g., IL-10, TGF-β), thus allowing tumors to evade the immune response.

In many cancers, a robust T cell infiltrate is correlated with a better overall survival, lower rates of relapse, and improved responses to therapy.
Assessing the type, density, and activation state of T cells in the tumor microenvironment can provide valuable prognostic information. High levels of active, cytotoxic T cells generally indicate a better prognosis.
Colon, Colon Cancer: Click to Expand ⟱
Colon cancer can start anywhere in the colon, (5 feet long) and absorbs water from stool. Rectal cancer starts in the rectum, which is the last 12 centimeters.
Scientific Papers found: Click to Expand⟱
8212- LCA,    Licochalcone A inhibits proliferation and promotes apoptosis of colon cancer cell by targeting programmed cell death-ligand 1 via the NF-κB and Ras/Raf/MEK pathways
- in-vitro, Colon, HepG3 - in-vitro, Lung, A549 - in-vitro, Cerv, HeLa - vitro+vivo, CRC, HCT116
PD-L1↓, p65↓, RAS?, NF-kB↓, T-Cell↑, p‑MEK↓, p‑Raf↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics(tgid=3) ⓘ

p‑MEK↓, 1,   p‑Raf↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

RAS?, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

NF-kB↓, 1,   p65↓, 1,   PD-L1↓, 1,   T-Cell↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

PD-L1↓, 1,  
Total Targets: 8

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: T-Cell, T lymphocytes
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:31  Cells:%  prod#:%  Target#:300  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page